주식회사 유틸렉스

Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.

Han C, Kwon BS.

Abstract

Chimeric antigen receptor (CAR) T cells have outstanding therapeutic potential for treating blood cancers. The prospects for this technology have accelerated basic research, clinical translation and Big Pharma's investment in the field of T-cell therapeutics. This interest has led to the discovery of key factors that affect CAR T-cell efficacy and play pivotal roles in T-cell immunology. Herein, we introduce advances in adoptive immunotherapy and the birth of CAR T cells, and review CAR T-cell studies that focus on three important features: CAR constructs, target antigens and T-cell phenotypes. At last, we highlight novel strategies that overcome the tumor microenvironment and circumvent CAR T-cell side effects, and consider the future direction of CAR T-cell development.

KEYWORDS:

adoptive immunotherapy; cancer; chimeric antigen receptor T-cell

Immunotherapy. 2018 Mar;10(3):221-234. doi: 10.2217/imt-2017-0133.